Business context and reporting period
This is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2018 (the company’s fiscal second quarter), not an Edesa Biotech filing as indicated in the request metadata. Stellar develops, manufactures and sells Keyhole Limpet Hemocyanin (KLH) for biotechnology and pharmaceutical customers and conducts related aquaculture and research activities. Financial figures are in U.S. dollars.
Financial results and position
| Metric | Three months ended March 31, 2018 | Six months ended March 31, 2018 |
|---|---|---|
| Revenue | $64,052 | $84,539 |
| Operating loss | $1,343,857 | $2,733,736 |
| Net loss | $1,352,527 | $2,753,273 |
| Basic and diluted loss per share | $0.90 | $1.83 |
| Operating cash flow | Not separately reported | $(2,532,868) |
At March 31, 2018, cash and cash equivalents were $3.29 million and short-term U.S. Treasury investments were $0.50 million, totaling approximately $3.79 million. Working capital was approximately $3.68 million; total assets were $5.33 million, current liabilities $0.59 million, and shareholders’ equity $4.74 million. The balance sheet reports no debt. Six-month capital expenditures were $205,891. No gross-margin percentage is stated; six-month cost of sales and contract services was $68,424 against $84,539 of revenue.
Material changes versus prior comparable periods
- Six-month revenue fell to $84,539 from $204,875, mainly due to lower product sales; contract-services revenue was zero versus $50,000.
- Six-month net loss widened to $2.75 million from $2.59 million. R&D rose to $1.12 million from $0.79 million, largely for manufacturing scale-up and throughput work; G&A declined to $1.45 million from $1.68 million.
- Quarterly revenue was approximately flat at $64,052 versus $63,019, while quarterly net loss widened to $1.35 million from $1.10 million. Quarterly R&D increased to $493,873 from $329,371.
- Cash and short-term investments declined from $6.57 million at September 30, 2017 to $3.79 million at March 31, 2018. The company used $2.53 million in operating cash during the six-month period.
Outlook, risks and unusual items
Management expects continuing losses and plans to fund near-term operations with cash on hand and product sales, while controlling expenditures, expanding its customer base and seeking additional debt or equity financing. No financing commitment had been secured. The filing states that, without additional capital, substantial doubt exists about the company’s ability to continue as a going concern beyond one year after issuance of the financial statements.
Product sales depend on the timing and progress of customers’ clinical programs, making sales volumes variable. Revenue was concentrated: two customers accounted for 72% of six-month revenue, compared with 88% in the prior-year period. The Neostell joint-venture milestone deadline was extended to December 31, 2018. The company reported $289,000 of future minimum lease payments and approximately $153,000 of purchase commitments, expected to be fulfilled within 12 months. It reported no material off-balance-sheet arrangements or material legal proceedings outside the ordinary course.
After quarter-end, the company effected a 1-for-7 reverse share split on May 4, 2018. Historical share and per-share figures in the filing reflect the split. Management concluded disclosure controls were effective as of March 31, 2018; no material changes to internal control were reported.
Most important facts to verify
- Confirm the filing is for Stellar Biotechnologies, Inc.; it does not appear to be an Edesa Biotech filing.
- Assess cash runway and financing needs in light of operating cash use and the stated going-concern uncertainty.
- Track KLH demand, customer clinical-trial progress, customer concentration and the effect on product sales.
- Verify progress on manufacturing scale-up investments and the Neostell joint venture before its extended deadline.
- Account for the May 4 reverse split when comparing share counts, warrants, options and per-share data.